Position in SABS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$171,923
+$171,647 QoQ
Shares Held
44,083
+72167.2% QoQ
Ownership
0.048%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#46
of 86 holders
Holding Since
Jun 2022
9 quarters on record
Voting authority
Sole 83%
Shared 0%
None 17%
Common Shares in SABS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026WELLS FARGO & COMPANY/MN holds $1,567,774,320 across 417 Biotechnology names. SABS ranks #259 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
749,528 | $372,313,040 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
1,390,428 | $108,828,797 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
310,047 | $93,333,446 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
140,802 | $87,795,677 | |
| 5 | EXEL |
Exelixis, Inc.
|
717,840 | $39,057,673 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
178,780 | $33,481,916 | |
| 7 | ARGX |
Argenx SE
|
34,453 | $31,964,458 | |
| 8 | INCY |
Incyte Corp
|
255,064 | $28,914,053 |
All Filings in SABS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $171,923 | 44,083 | Shares | Defined | 2026-08-14 | |
| 2024-03-31 | $276 | 61 | Shares | Defined | 2024-05-10 | |
| 2023-12-31 | $202 | 294 | Shares | Defined | 2024-02-09 | |
| 2023-09-30 | $168 | 268 | Shares | Defined | 2023-11-13 | |
| 2023-06-30 | $205 | 247 | Shares | Defined | 2023-08-15 | |
| 2023-03-31 | $82 | 187 | Shares | Defined | 2023-05-12 | |
| 2022-12-31 | $109 | 185 | Shares | Defined | 2023-02-13 | |
| 2022-09-30 | $126 | 180 | Shares | Defined | 2022-11-14 | |
| 2022-06-30 | $242 | 167 | Shares | Defined | 2022-08-12 | |
| No filing history on record for this holder in this stock. | ||||||